Announcements Trials
Browse Landscape

Phase

Phase 1 7Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Endometrial Neoplasms 3Breast Neoplasms 3Sarcoma 2Prostatic Neoplasms 2Neoplasms 2Recurrence 1Primary Myelofibrosis 1Osteosarcoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancers 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × ridaforolimus × Clear all
NCT00110188 2015-11-20

Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Merck Sharp & Dohme LLC

Phase 2 Completed
39 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT00122343 2015-02-19

AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
45 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡